Archive for December, 2005
December 14th, 2005. Treatment of thoracic malignancy – results of meta-analyses
Abstract Meta-analyses dealing with the treatment of thoracic malignancy (non-small cell lung cancer, small cell lung cancer and mesothelioma) were reviewed including isolated ones, based on individual data from clinical trials, or conducted in the context of a systematic review of the literature Their results have changed clinical practice, notably by validating radiochemotherapy for patients with unresectable limited diseases, adjuvant chemotherapy for resectable non-small cell lung cancer and by identifying the most active drugs. However it is important to understand the limits of their methodology in order to avoid inappropriate interpretations.
December 10th, 2005. Neurofibromatosis 2 (NF2) and Malignant Mesothelioma in a Man with a Constitutional NF2 Missense Mutation
We report an elderly man with NF2, malignant mesothelioma, and a constitutional NF2 missense mutation. The long latent period for mesothelioma in this patient (61 years) raises the possibility that the type of mutant NF2 allele could affect mesothelioma tumorigenesis or progression.
December 8th, 2005. Monoclonal antibody MOC-31 reactivity as a marker for adenocarcinoma in cytologic preparations
Conclusions: On the basis of the staining profile, MOC-31 represented an effective marker for metastatic carcinoma in cell block preparations and may aid in distinguishing between benign and malignant mesothelial cells in these tumors. Cancer (Cancer Cytopathol) 2006. © 2006 American Cancer Society.
December 8th, 2005. Diagnosi precoce e terapie integrate del mesotelioma pleurico maligno
palliative, proved to be useful in the treatment of two major symptoms, namely dyspnea and thoracic pain. In this work the Authors are reporting their experience with malignant pleural mesothelioma, stressing the role of videothoracoscopy in the early diagnosis, weighing the radical cancer resection option and the effectiveness of multimodal treatment.
December 8th, 2005. The potential of proton beam radiation therapy in lung cancer (including mesothelioma)
The estimations have been based on current statistics of tumour incidence, number of patients potentially eligible for radiation treatment, scientific support from clinical trials and model dose planning studies and knowledge of the dose-response relations of different tumours and normal tissues. It is estimated that about 350 patients with lung cancer and about 20 patients with mesothelioma annually may benefit from proton beam therapy.
December 7th, 2005. The Immunohistochemical Profile of Malignant Mesotheliomas of the Tunica Vaginalis: A Study of 20 Cases
Focal weak positivity may be encountered with BerEp4. However, histopathologists should be aware of the variability in CK5-6 staining in testicular specimens when compared with pleural mesotheliomas.
December 6th, 2005. Nonpleural mesotheliomas: mesothelioma of the peritoneum, tunica vaginalis, and pericardium
Mesotheliomas that involve the pericardium or originate from the tunica vaginalis are rare tumors. Given the rarity of these tumors, it is difficult to obtain precise information regarding their incidence, natural history, and optimal management.
December 6th, 2005. Multimodality treatments in the management of malignant pleural mesothelioma: an update
In most cases there is no sufficient time for systemic disease to develop or contribute to mortality. The first order of therapy in MPM is currently, as it has been for decades, to control effectively the tumor's locoregional spread and then deal with controlling the distant disease.
December 6th, 2005. Radiotherapy for mesothelioma
Locoregional tumor recurrence can be eliminated with combinations of extrapleural pneumonectomy and radiation therapy. Survival in early-stage patients is excellent.
December 6th, 2005. An overview of chemotherapy for mesothelioma
Finally, new agents currently under study are discussed. Other excellent reviews that have been published recently offer the reader further information on this topic.
December 6th, 2005. Antiangiogenic therapies for mesothelioma
Several clinical trials are currently evaluating the efficacy of inhibitors of angiogenesis in mesothelioma. This article details the preliminary results of these trials and future directions.
December 6th, 2005. Gene therapy for malignant pleural mesothelioma
Unfortunately, the marginal benefits garnered from standard anticancer treatments in mesothelioma argue strongly for continued participation in clinical studies of various experimental approaches, particularly gene therapy. These trials serve multiple purposes: to establish safety, determine proper dosing, evaluate for efficacy, and, in an iterative fashion, guide future avenues of laboratory investigation.
December 6th, 2005. Mesothelioma from the Patient’s Perspective
The results illustrate the severe disease burden that is borne by people who have mesothelioma. It is hoped that a greater understanding of mesothelioma from a patient's perspective could inform the response of health care professionals.
December 6th, 2005. Malignant Pleural Mesothelioma: A Case Report
Conclusion: This is an unusual case of advanced MPM that is most likely from indirect asbestos exposure. Key Indexing Terms: Asbestos; Asbestosis; Mesothelioma; Pleural neoplasms; Chiropractic
December 6th, 2005. A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors
Conclusions: This schedule allows oxaliplatin and gemcitabine to be delivered at the full dose intensity of each drug with excellent tolerability and predictable pharmacokinetics. The recommended doses for phase II studies are oxaliplatin 70 mg/m2 and gemcitabine 1,250 mg/m2 on days 1 and 8 every 21 days.
December 3rd, 2005. Fluorescence Detection of Pleural Malignancies Using 5-Aminolaevulinic Acid
Conclusions: FD using 5-ALA in the pleural cavity is feasible with limited side effects when used in addition to white light inspection. It improved visualization of abnormal lesions and led to upstaging in 4 of 15 mesothelioma patients. Key Words: aminolaevulinic acid • fluorescence detection • pleural malignancies • polymeric photonic display
December 2nd, 2005. Autofluorescence videothoracoscopy in exudative pleural effusions: preliminary results
In conclusion, the calculated positive predictive value of colour change for malignant pleuritis during autofluorescence thoracoscopy in this study was 92%. However, the clinical value of autofluorescence thoracoscopy in daily practice remains to be proven.
December 2nd, 2005. Similar Tumor Suppressor Gene Alteration Profiles in Asbestos-Induced Murine and Human Mesothelioma
These data show that the profile of TSG alterations in asbestos-induced mesothelioma is similar in mice and humans. Thus, the mouse mesothelioma model could be useful for human risk assessment, taking into account interindividual variations in genetic sensitivity to carcinogens.
December 2nd, 2005. Use of Tunneled Pleural Catheters in Malignant Mesothelioma
Conclusion: TPC are as effective in patients with MM as in other patients with malignant pleural effusions. Use of TPC should be considered for the palliation of malignant pleural effusions associated with MM.
December 2nd, 2005. A case of ascities decrease in malignant peritoneal mesothelioma by weekly intra-peritoneal administration of cisplatin and paclitaxel
MPM was poor in prognosis and the control of ascites was difficult. We suggest that the chemotherapy of intra-peritoneal administration was a better procedure than others to control ascites with malignant tumors.
|
|  |
